Hawaii AIDS Clinical Trials Unit (HACTU) is part of the HTV clinicalresearch arm of the University of Hawaii's program in Retrovirology. HACTU has been a formal unitofthe Adult AIDS Clinical Trials Group(AACTG) since 1990 with funding received under a minority institution initiative. Our site brings to the Adult AIDS ClinicalTrials Group: 1) An established clinical trials unit within the AACTG with a track record for excellence in clinical trial management, currently meeting all ACTG standards for site operations; 2)Access to Hawaii's ethnically diverse population, havingpreviously contributed41% of all ACTG's enrollees of Asian/Pacific Islander descent; 3) A unitwithwide community,state governmental and university support for its operations as the.only HTV/AIDSclinical research program in Hawaii; 4) A continued commitment tc participate as broadly as feasible not only in AACTG's main anti-retro viral trials but also in specialized areas of HIV immunology and complication research targeted as areas of special importance bythe AACTG leadership; 5) A minority uni with a record of increasing scientific contributionsto the ACTG over the past 5 years and a commitment to contribute tothe AACTG's scientific agenda in the next 5 years specifically in the areas of: pathogenesis/treatment of HIV/Hepatitis Banc C co-infection, HTV-associatedmetaboliccomplications, role of insertional metagenesis andmacrophages inthe pathogenesi; of HIV-associated malignancies and CNS disease and in the impactof menopause and femalereplacement hormonal therapj on HIV-1 activity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI034853-12S4
Application #
7547393
Study Section
Special Emphasis Panel (ZAI1-PSS-A (S1))
Program Officer
Power, Maureen E
Project Start
1996-01-01
Project End
2008-11-30
Budget Start
2008-01-15
Budget End
2008-11-30
Support Year
12
Fiscal Year
2008
Total Cost
$233,159
Indirect Cost
Name
University of Hawaii
Department
Type
Schools of Medicine
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Vardhanabhuti, Saran; Ribaudo, Heather J; Landovitz, Raphael J et al. (2015) Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis 2:ofv085
Thio, Chloe L; Smeaton, Laura; Hollabaugh, Kimberly et al. (2015) Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS 29:1173-82

Showing the most recent 10 out of 114 publications